Invitae offers gene panels and single-gene testing for a broad range of clinical areas including hereditary cancer, cardiology, neurology, pediatric genetics, metabolic disorders, immunology, and hematology.
The price is on a strong weekly pattern, decent long opportunity on probable bullish rebound.
Back in June 20, NVTA jumped up rather spectacularly and since late Jan 21, bears are beating it down.
24.90 was a critical point but we crashed it down and due to Jun 20 pump up, we are right now in the vacuum between a solid support of 15 and 25.
20 was a resistance in the past, we don`t know whether it will work as a support but my main point is that this gap...
Hello dear padawans. Short and sweet analysis on Invitae:
$NVTA on long term support. It is also oversold. Given the lower shadow of current candle investors have strong appetite for current prices
On the flip side one could venture reading the long term formation as a head and shoulders pattern.
If you are a long term investor, buying here is a no brainer...
$NVTA Target 36.47 for 34.08%
Or next add at 25.15
-----
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
ONLY ADD at support levels & FIB levels… labeled
I start every position with .5 - 1% of my account and build from there as needed and as possible.
I am...
Chatter over a possible merger of Invitae with Exact Science and it it does, buy the rumours, sell on news. There is a nice double bottom but would want to wait till it surpassed $35/36 before seeing it surging up. Also have to look out to see if NVTA could form a higher highs form and create a solid uptrend. Keep monitoring the price action and watch out for the news!!
$NVTA Target 37.64 for 32.68%
Or next add at 26.02
-----
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
ONLY ADD at support levels & FIB levels… labeled
I start every position with .5 - 1% of my account and build from there as needed and as possible.
I am...
Possible breakout target around $43. ( one of ARKG stocks)
- Buy call option strike $35 , July-16 @ $1
Nvitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W....
$NVTA Target 37.64 for 32.68%
Or next add level is at 19.10
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
I start every position with 1% of my account and build from there as needed and as possible.
I am not your financial advisor. Watch my setups first...
Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.
If you want not to miss ideas like this one ,🎯 subscribe and press a...
Hello everyone,
I hope you are all doing well!
In this analysis, we have broken through the bigger channel and the fall is moving in a smaller channel.
We are sitting on a truly KEY SUPPORT that I beleive we are going to hold and go to the $43 mark.
There is possibility of more bad news and break lower. The lowest point would be $19 and from then on, we would...
Clean pattern NVTA.. could be a Gartley to $34 area for a retrace.. look for shorts to cover there and we retrace some of downward move.
As with any trade manage positions properly.
A symmetrical triangle is a chart pattern characterized by two converging trend lines connecting a series of sequential peaks and troughs. These trend lines should be converging at a roughly equal slope.
NVTA is going back to the channel. We can see an inverse head and shoulder pattern of a whale that will appear soon to catapult it back to the mid-50s.
Invitae's Q4 results remained the same as in previous quarters. The company has shown strong revenue growth, but remains consistently unprofitable.
At the end of 2020, the company conducted 659,000 tests, which is 36.7% more than in 2019.
Net loss was $ 608.9 million, or $ 4.52 per share, up from $ 242.0 million, or $ 2.66 per share, in the prior year.
The...
I love the ARK invest stock. I've been eyeing this one for months I think its high time I pounce on it like a roaring kitty.
***This does not constitute financial advice.***
Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.
NYSE
